AARON'S COMPANY INC. O.N.

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG  Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids SPRING HOUSE, Pa. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.» Mehr auf prnewswire.com

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.» Mehr auf globenewswire.com

SASKATOON, Saskatchewan, March 06, 2025 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) is pleased to announce that it has entered into an Exploration Agreement (“EA”) with Apitipi Anicinapek Nation (“AAN”) with respect to the Company's Goldarm Property (“Goldarm” or the “Project”) located in the world-class Timmins Gold District of Ontario, Canada. The EA sets the stage for continuous consultation with AAN, providing the community with the chance to engage in the Project through employment, training, and business growth opportunities. As outlined in the EA, GFG will allocate contributions to a community fund based on its exploration expenses in AAN territory. Furthermore, within 10 business days of TSXV approval, the Company will issue $20,000 in GFG common shares to AAN. GFG will calculate the number of shares based on the average closing price of the shares for the five days preceding this announcement, or such alternative pricing as may be approved by the TSXV. The EA remains subject to the approval of the TSXV.» Mehr auf globenewswire.com